Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

奥佐美星 医学 内科学 卡奇霉素 髓系白血病 化疗 血液学 外科 随机对照试验 胃肠病学 临床终点 CD33 川地34 干细胞 遗传学 生物
作者
Sylvie Castaigné,Cécile Pautas,Christine Terré,Emmanuel Raffoux,Dominique Bordessoule,Jean-Noel Bastie,Ollivier Legrand,Xavier Thomas,Pascal Turlure,Oumédaly Reman,Thierry de Revel,Lauris Gastaud,Noémie de Gunzburg,Nathalie Contentin,Estelle Henry,Jean‐Pierre Marolleau,Ahmad Aljijakli,Philippe H. Rousselot,Pierre Fenaux,Claude Preudhomme
出处
期刊:The Lancet [Elsevier BV]
卷期号:379 (9825): 1508-1516 被引量:1055
标识
DOI:10.1016/s0140-6736(12)60485-1
摘要

Background The results of the addition of gemtuzumab ozogamicin, an anti-CD33 antibody conjugate, to the standard treatment for patients with acute myeloid leukaemia in phase 3 trials were contradictory. We investigated whether the addition of low fractionated-dose gemtuzumab ozogamicin to standard front-line chemotherapy would improve the outcome of patients with this leukaemia without causing excessive toxicity. Methods In a phase 3, open-label study, undertaken in 26 haematology centres in France, patients aged 50–70 years with previously untreated de novo acute myeloid leukaemia were randomly assigned with a computer-generated sequence in a 1:1 ratio with block sizes of four to standard treatment (control group) with or without five doses of intravenous gemtuzumab ozogamicin (3 mg/m2 on days 1, 4, and 7 during induction and day 1 of each of the two consolidation chemotherapy courses). The primary endpoint was event-free survival (EFS). Secondary endpoints were relapse-free (RFS), overall survival (OS), and safety. Analysis was by intention to treat. This study is registered with EudraCT, number 2007-002933-36. Findings 280 patients were randomly assigned to the control (n=140) and gemtuzumab ozogamicin groups (n=140), and 139 patients were analysed in each group. Complete response with or without incomplete platelet recovery to induction was 104 (75%) in the control group and 113 (81%) in the gemtuzumab ozogamicin group (odds ratio 1·46, 95% CI 0·20–2·59; p=0·25). At 2 years, EFS was estimated as 17·1% (10·8–27·1) in the control group versus 40·8% (32·8–50·8) in the gemtuzumab ozogamicin group (hazard ratio 0·58, 0·43–0·78; p=0·0003), OS 41·9% (33·1–53·1) versus 53·2% (44·6–63·5), respectively (0·69, 0·49–0·98; p=0·0368), and RFS 22·7% (14·5–35·7) versus 50·3% (41·0–61·6), respectively (0·52, 0·36–0·75; p=0·0003). Haematological toxicity, particularly persistent thrombocytopenia, was more common in the gemtuzumab ozogamicin group than in the control group (22 [16%] vs 4 [3%]; p<0·0001), without an increase in the risk of death from toxicity. Interpretation The use of fractionated lower doses of gemtuzumab ozogamicin allows the safe delivery of higher cumulative doses and substantially improves outcomes in patients with acute myeloid leukaemia. The findings warrant reassessment of gemtuzumab ozogamicin as front-line therapy for acute myeloid leukaemia. Funding Wyeth (Pfizer).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
isabellae完成签到,获得积分10
1秒前
wanci的应助被花鸢采纳,获得10
1秒前
botao_li关注了科研通微信公众号
1秒前
yuhenghou完成签到,获得积分10
1秒前
An22发布了新的文献求助10
1秒前
小鹿呀完成签到,获得积分10
1秒前
于生有你发布了新的文献求助10
2秒前
2秒前
JOJO完成签到,获得积分10
2秒前
干净老姆完成签到,获得积分10
3秒前
柚子完成签到,获得积分10
3秒前
ZX发布了新的文献求助10
4秒前
wangbw完成签到,获得积分10
4秒前
空白完成签到,获得积分10
4秒前
南川完成签到,获得积分10
5秒前
英姑的应助被颖颖采纳,获得10
5秒前
Wayne完成签到,获得积分10
5秒前
kuikui1100完成签到,获得积分10
5秒前
Daria完成签到 ,获得积分10
5秒前
wang完成签到 ,获得积分10
6秒前
刚刚好完成签到,获得积分10
6秒前
CC完成签到 ,获得积分10
6秒前
彭彭完成签到 ,获得积分10
7秒前
华仔的应助被你在烦恼什么采纳,获得10
7秒前
h7nho完成签到,获得积分10
7秒前
8秒前
CJT完成签到 ,获得积分10
8秒前
下雨天完成签到,获得积分10
8秒前
yy完成签到 ,获得积分10
9秒前
小居同学完成签到,获得积分10
9秒前
科研通AI6.2的应助被阿信苏采纳,获得10
9秒前
9秒前
10秒前
AAAA完成签到,获得积分10
10秒前
yxl发布了新的文献求助10
11秒前
科研通AI65的应助被呆萌的晓槐采纳,获得10
11秒前
Rhea完成签到,获得积分10
11秒前
过时的亦寒完成签到,获得积分10
11秒前
知性的紫寒完成签到,获得积分10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180135
求助须知:如何正确求助?哪些是违规求助? 9570290
关于积分的说明 21809391
捐赠科研通 7776237
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557465
邀请新用户注册赠送积分活动 2479039